ProCE Banner Activity

CheckMate 9LA: 2-Yr Update of First-line Nivolumab + Ipilimumab With 2 Cycles of Chemotherapy vs Chemotherapy Alone in Advanced NSCLC

Slideset Download
Conference Coverage
First-line nivolumab plus ipilimumab with chemotherapy continued to provide durable clinical benefit in patients with advanced NSCLC regardless of PD-L1 expression with extended follow-up.

Released: June 10, 2021

Expiration: June 09, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme